| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
22,545 |
21,177 |
$2.12M |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
9,418 |
8,508 |
$1.85M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
6,534 |
6,158 |
$1.24M |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
5,003 |
4,796 |
$1.23M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
6,654 |
6,375 |
$728K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
4,980 |
1,711 |
$425K |
| 80053 |
Comprehensive metabolic panel |
7,886 |
7,281 |
$403K |
| 36415 |
Collection of venous blood by venipuncture |
4,244 |
3,912 |
$401K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
1,634 |
1,602 |
$338K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
3,688 |
2,878 |
$321K |
| 99215 |
Prolong outpt/office vis |
532 |
524 |
$190K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
1,781 |
1,744 |
$181K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
387 |
377 |
$128K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
439 |
431 |
$125K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
2,076 |
788 |
$119K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
4,375 |
3,588 |
$113K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
301 |
271 |
$104K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
988 |
972 |
$98K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
404 |
404 |
$67K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
617 |
365 |
$57K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
417 |
407 |
$56K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
268 |
268 |
$52K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
343 |
329 |
$48K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,051 |
926 |
$47K |
| 81025 |
|
180 |
178 |
$37K |
| 80061 |
Lipid panel |
2,634 |
2,612 |
$25K |
| 84443 |
Thyroid stimulating hormone (TSH) |
3,212 |
3,161 |
$21K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
657 |
653 |
$21K |
| 70450 |
Computed tomography, head or brain; without contrast material |
50 |
49 |
$17K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
407 |
347 |
$16K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
187 |
187 |
$16K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
43 |
43 |
$14K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
214 |
210 |
$13K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
7,503 |
6,766 |
$12K |
| 99441 |
|
461 |
457 |
$12K |
| 99442 |
|
315 |
309 |
$11K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
1,817 |
1,798 |
$11K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
66 |
66 |
$9K |
| 82607 |
|
1,061 |
1,050 |
$9K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
48 |
47 |
$8K |
| 90686 |
|
212 |
212 |
$7K |
| 0012A |
|
195 |
194 |
$6K |
| 0011A |
|
218 |
218 |
$6K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
123 |
123 |
$5K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
214 |
210 |
$5K |
| 97161 |
|
50 |
50 |
$5K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
1,665 |
1,613 |
$4K |
| 84439 |
|
589 |
583 |
$4K |
| 99173 |
|
297 |
297 |
$4K |
| 81001 |
|
2,302 |
2,235 |
$4K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
25 |
24 |
$4K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
35 |
34 |
$4K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
200 |
200 |
$4K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
463 |
461 |
$3K |
| 82043 |
|
765 |
756 |
$3K |
| 82570 |
|
784 |
774 |
$3K |
| 97162 |
|
30 |
30 |
$3K |
| 0031A |
|
94 |
94 |
$2K |
| 84702 |
|
1,034 |
974 |
$2K |
| 83735 |
|
1,242 |
1,108 |
$2K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
1,669 |
829 |
$2K |
| 82728 |
|
244 |
241 |
$2K |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
12 |
12 |
$2K |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
172 |
165 |
$2K |
| 84481 |
|
216 |
213 |
$2K |
| 71046 |
Radiologic examination, chest; 2 views |
451 |
442 |
$1K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
1,361 |
1,299 |
$1K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
1,362 |
1,302 |
$1K |
| 87077 |
|
492 |
486 |
$1K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
1,052 |
1,002 |
$989.31 |
| 99201 |
|
49 |
49 |
$977.89 |
| 85610 |
|
896 |
794 |
$847.36 |
| 83540 |
|
259 |
256 |
$805.69 |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
107 |
97 |
$802.50 |
| 83550 |
|
228 |
225 |
$787.61 |
| 82746 |
|
82 |
82 |
$690.60 |
| 99443 |
|
13 |
13 |
$665.64 |
| 81003 |
|
1,756 |
1,693 |
$600.94 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
97 |
95 |
$523.03 |
| 87186 |
|
278 |
274 |
$418.76 |
| 71045 |
Radiologic examination, chest; single view |
693 |
668 |
$333.80 |
| 86618 |
|
39 |
39 |
$272.48 |
| 83690 |
|
329 |
314 |
$220.85 |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
1,378 |
1,324 |
$203.85 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
458 |
445 |
$202.17 |
| 85730 |
|
424 |
413 |
$174.79 |
| 84484 |
|
747 |
701 |
$164.30 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
70 |
65 |
$114.75 |
| 85049 |
|
469 |
421 |
$110.67 |
| 85652 |
|
57 |
55 |
$67.09 |
| 73610 |
|
38 |
37 |
$65.69 |
| 86140 |
|
17 |
17 |
$45.54 |
| 87634 |
|
249 |
248 |
$43.28 |
| 87070 |
|
14 |
14 |
$40.75 |
| 73130 |
|
13 |
13 |
$22.74 |
| 85379 |
|
40 |
40 |
$20.36 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
176 |
162 |
$16.57 |
| 82947 |
|
14 |
12 |
$14.55 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,366 |
1,030 |
$14.05 |
| 87205 |
|
12 |
12 |
$13.60 |
| 73630 |
|
38 |
38 |
$7.50 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
167 |
133 |
$3.14 |
| J2704 |
Injection, propofol, 10 mg |
14 |
12 |
$0.99 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
54 |
40 |
$0.98 |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
13 |
12 |
$0.82 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
837 |
786 |
$0.67 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
33 |
31 |
$0.24 |
| 90461 |
|
12 |
12 |
$0.00 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
21 |
20 |
$0.00 |
| 73110 |
|
12 |
12 |
$0.00 |
| 85008 |
|
375 |
331 |
$0.00 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
52 |
45 |
$0.00 |